The heterozygous reeler mouse: Behavioural phenotype

Behavioural Brain Research

Volumn 153, Issue 1, 2004, Pages 43-54

  Podhorna, Jana ^a   Didriksen, Michael ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

+ rl; AMP; amphetamine; GAD; glutamic acid decarboxylase; Light dark transition test; Mutant mice; N methyl D aspartate; NMDA; PCP; phencyclidine; Prepulse inhibition; reeler wild type mice; Reeler wild type mice (+ rl); Social behaviour; Spontaneous locomotion

Indexed keywords

DEXAMPHETAMINE; PHENCYCLIDINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENETICS; LIGHT DARK CYCLE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PERFORMANCE; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION; STARTLE REFLEX;

ACOUSTIC STIMULATION; AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GENETICS, BEHAVIORAL; HETEROZYGOTE; INHIBITION (PSYCHOLOGY); MALE; MICE; MICE, NEUROLOGIC MUTANTS; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PAIN MEASUREMENT; PHENCYCLIDINE; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SEX FACTORS; SOCIAL BEHAVIOR; STARTLE REACTION;

EID: 3042544069     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2003.10.033     Document Type: Article

References (38)

1. Rowley M., Bristow L.J., Hutson P.H. Current and novel approaches to the drug treatment of schizophrenia. J. Med. Chem. 44:2001;477-501
2. Salinger W.L., Ladrow P.L., Wheeler C.B. Behavioural phenotype of the Reeler mutant mouse: Effects of Reln gene dosage and social isolation. Behav. Neurosci. 117:2003;1257-1275
3. Groves J.O., O'Meara G.F., Handford E.J., Smith D., Dawson G.R., Reynolds D.S. Evaluation of the heterozygous reeler mouse as a potential model for schizophrenia. J. Psychopharmacol. 17:2003;A43
4. Costa E., Davis J., Pesold C., Tueting P., Guidotti A. The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr. Opin. Pharmacol. 2:2002;56-62
5. Gilmore EC, Herrup K. Cortical development: receiving reelin. Curr Biol 2000;10:R162-6.
6. D'Arcangelo G., Curran T. Reeler: new tales on an old mutant mouse. Bioessays. 20:1998;235-244
7. Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998;95:15718-23.
8. Pesold C, Impagnatiello F, Pisu MG, Uzunov DP, Costa E, Guidotti A, et al. Reelin is preferentially expressed in neurons synthesizing gamma-aminobutyric acid in cortex and hippocampus of adult rats. Proc Natl Acad Sci USA 1998;95:3221-6.
9. Pesold C., Liu W.S., Guidotti A., Costa E., Caruncho H.J. A reelin haplo-insufficiency may underlie some of the neuroanatomical abnormalities found in schizophrenic brain. Soc. Neurosci. Abst. 25:1999;1293. [A520.4]
10. Eastwood S.L., Harrison P.J. Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. Mol. Psychiatry. 8:2003;821-831
11. Tueting P, Costa E, Dwivedi Y, Guidotti A, Impagnatiell F, Manev R, et al. The phenotypic characteristics of heterozygous reeler mouse. Neuroreport 1999;10:1329-34.
12. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am. J. Psychiatry. 155:1998;1661-1670
13. D'Arcangelo G., Miao G.G., Curran T. Detection of the reelin breakpoint in reeler mice. Brain Res. Mol. Brain Res. 39:1996;234-236
14. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 13:1968;222-257
15. Grant E.C., Mackintosh J.H. A comparison of the social postures of some common laboratory rodents. Behaviour. 21:1963;246-259
16. Krsiak M. Timid singly-housed mice: their value in prediction of psychotropic activity of drugs. Br. J. Pharmacol. 55:1975;141-150
17. A receptors. Soc. Neurosci. Abst. 26:2000;1058. [A396.9]
18. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry. 51:1994;139-154
19. Grillon C, Morgan CA, Southwick SM, Davis M, Charney DS. Baseline startle amplitude and prepulse inhibition in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res 1996;64:169-78.
20. Grillon C, Morgan CA, Davis M, Southwick SM. Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder. Biol Psychiatry 1998;44:1027-36.
21. Ludewig S., Ludewig K., Geyer M.A., Hell D., Vollenweider F.X. Prepulse inhibition deficits in patients with panic disorder. Depress Anxiety. 15:2002;55-60
22. Swerdlow N.R., Benbow C.H., Zisook S., Geyer M.A., Braff D.L. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol. Psychiatry. 33:1993;298-301
23. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 7:1996;3-23
24. Nagai T, Noda Y, Une T, Furukawa K, Furukawa H, Kan QM, et al. Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. Neuroreport 2003;14:269-72.
25. Curzon P., Decker M.W. Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;129-146
26. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214
27. Lahti A.C., Weiler M.A., Michaelidis T., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacol. 25:2001;455-467
28. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 10:1999;59-90
29. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 6:1995;55-65
30. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl.). 92:1987;180-185
31. Lister R.G. Ethologically-based animal models of anxiety disorders. Pharmacol. Ther. 46:1990;321-340
32. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Tomkins D.M. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol. Biochem. Behav. 22:1989;777-785
33. Liljequist S. Genetic differences in the effects of competitive and non-competitive NMDA receptor antagonists on locomotor activity in mice. Psychopharmacology (Berl.). 104:1991;17-21
34. Xu X., Domino E.F. Genetic differences in the locomotor response to single and daily doses of phencyclidine in inbred mouse strains. Behav. Pharmacol. 5:1994;623-629
35. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999;98:427-36.
36. Alter M., Liebo J., Desnick S.O., Strommer B. The behavior of the reeler neurological mutant mouse. Neurology. 18:1968;289
37. Myers W.A. Some observations on "reeler", a neuromuscular mutation in mice. Behav. Genet. 1:1970;225-234
38. Goldowitz D., Koch J. Performance of normal and neurological mutant mice on radial arm maze and active avoidance tasks. Behav. Neural. Biol. 46:1986;216-226